Zonisamide has beneficial effects on Parkinson's disease patients

被引:114
|
作者
Murata, M [1 ]
Horiuchi, E [1 ]
Kanazawa, I [1 ]
机构
[1] Univ Tokyo, Grad Sch Med, Dept Neurol, Bunkyo Ku, Tokyo 1138655, Japan
关键词
zonisamide; Parkinson's disease; levodopa; anticonvulsant;
D O I
10.1016/S0168-0102(01)00298-X
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Zonisamide (ZNS) is a generally well tolerated anticonvulsant that has beneficial effects on Parkinson's disease (PD). ZNS (300 mg/day) given to a patient with PD who incidentally had convulsive attacks, ameliorated the attacks and, surprisingly, his parkinsonian symptoms. We, therefore, carried out an open trial of ZNS on nine patients with PD. Patients were given 50-200 mg/day ZNS in addition to their anti-PD drugs. Seven clearly showed lessening of symptoms, especially wearing-off. We speculate that long lasting activation of dopamine synthesis by ZNS ameliorates parkinsonian symptoms, in particular wearing-off. (C) 2001 Elsevier Science Ireland Ltd and the Japan Neuroscience Society. All rights reserved.
引用
收藏
页码:397 / 399
页数:3
相关论文
共 50 条
  • [21] Repetitive transcranial magnetic stimulation has a beneficial effect on bradykinesia in Parkinson's disease
    Siebner, HR
    Mentschel, C
    Auer, C
    Conrad, B
    NEUROREPORT, 1999, 10 (03) : 589 - 594
  • [22] Zonisamide's effects in Parkinson's disease patients with tremor; a meta-analysis of three placebo-controlled studies
    Murata, M.
    Murahashi, Y.
    Shimazu, R.
    Nakamura, M.
    MOVEMENT DISORDERS, 2014, 29 : S253 - S253
  • [23] Zonisamide Enhances Motor Effects of Levodopa, Not of Apomorphine, in a Rat Model of Parkinson's Disease
    Nishijima, Haruo
    Miki, Yasuo
    Ueno, Shinya
    Tomiyama, Masahiko
    PARKINSONS DISEASE, 2018, 2018
  • [24] Galantamine has beneficial effects on aggression and agitation in patients with advanced moderate Alzheimer's disease
    Kurz, A
    Schwalen, S
    NEUROBIOLOGY OF AGING, 2002, 23 (01) : S120 - S121
  • [25] Actigraphic study of tremor before and after treatment with zonisamide in patients with Parkinson's disease
    Mochio, Soichiro
    Sengoku, Renpei
    Kono, Yu
    Morita, Masayo
    Mitsumura, Hidetaka
    Takagi, Satoshi
    Kamiyama, Tsutomu
    Oka, Hisayoshi
    PARKINSONISM & RELATED DISORDERS, 2012, 18 (07) : 906 - 908
  • [26] Preliminary study of zonisamide monotherapy in de novo patients with early Parkinson's disease
    Ikeda, Ken
    Sawada, Sayori Hanashiro Masahiro
    Iwasaki, Yasuo
    NEUROLOGY AND CLINICAL NEUROSCIENCE, 2015, 3 (05): : 163 - 166
  • [27] The beneficial effects of tolcapone (Tasmar) on sleep disability in Parkinson's disease patients with motor fluctuations
    Stiasny, K
    Deptula, D
    Dorflinger, E
    NEUROLOGY, 1998, 50 (04) : A262 - A263
  • [28] Zonisamide in managing impulse control disorders in Parkinson’s disease
    Pedro Emilio Bermejo
    Cristina Ruiz-Huete
    Buenaventura Anciones
    Journal of Neurology, 2010, 257 : 1682 - 1685
  • [29] Zonisamide in managing impulse control disorders in Parkinson's disease
    Bermejo, P. E.
    Velasco-Calvo, R.
    JOURNAL OF NEUROLOGY, 2008, 255 : 167 - 168
  • [30] Zonisamide Ameliorates Microglial Mitochondriopathy in Parkinson's Disease Models
    Tada, Satoshi
    Choudhury, Mohammed E.
    Kubo, Madoka
    Ando, Rina
    Tanaka, Junya
    Nagai, Masahiro
    BRAIN SCIENCES, 2022, 12 (02)